CureVac jumps into coronavirus vaccine race; EMA backs raft of drugs, including Novo Nordisk, Esperion compounds
→ You can add CureVac to the list of new players to jump into the latest effort to contain a pandemic. The mRNA company has joined the global crew already on board with the public-private Coalition for Epidemic Preparedness Innovations, which is adding up to $8.3 million to rapidly develop, manufacture and test a new vaccine for the coronavirus 2019-nCoV. The German biotech is the latest biotech to see if new tech can address a scary virus that evidently kills some 3% to 4% of the people who are infected by it. Others, including Moderna and Vir, are also using new tech developed over the last decade to see if they can come up with a quick way to stop the spread of the Wuhan virus, which is rattling populations around the world.
Unlock this article instantly by becoming a free subscriber.
You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.